Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis.
Mo XD, Hong SD, Zhao YL, Jiang EL, Chen J, Xu Y, Sun ZM, Zhang WJ, Liu QF, Liu DH, Wan DM, Mo WJ, Ren HY, Yang T, Huang H, Zhang X, Wang XN, Song XM, Gao SJ, Wang X, Chen Y, Xu B, Jiang M, Huang XB, Li X, Zhang HY, Wang HT, Wang Z, Niu T, Wang JS, Xia LH, Liu XD, Li F, Zhou F, Lang T, Hu J, Wu SJ, Huang XJ.
Mo XD, et al.
Am J Hematol. 2022 Apr;97(4):458-469. doi: 10.1002/ajh.26475. Epub 2022 Feb 4.
Am J Hematol. 2022.
PMID: 35064928
Free article.
Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). ...The cumulative incidence of overall response rate (ORR) at day 28 after basiliximab trea …
Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is one of the leading causes of early mortality after allogeneic hema …